Bronchiectasis Specialty
Demographics & Physiology
Assessment Pending
The Bronchiectasis Severity Index integrates clinical, microbiological, and radiological parameters to provide a 1-year risk profile.
Guidelines & Evidence
Verified
Last Review: 2026
When to Use
Primary Indications
Patients with confirmed non-cystic fibrosis bronchiectasis by high-resolution CT (HRCT)
Initial risk stratification at time of diagnosis to guide management intensity
Predicting 1-year, 2-year, 3-year, and 4-year mortality rates
Forecasting future hospitalization risk and exacerbation frequency
Identifying patients who may benefit from more aggressive therapy (macrolides, inhaled antibiotics, surgery)
Monitoring disease progression with serial assessments (annually or when clinical status changes)
Research inclusion criteria for clinical trials of novel bronchiectasis therapies
Clinical Utility
The BSI outperforms individual clinical parameters (FEV1%, age, exacerbation history alone) in predicting prognosis. A BSI score ≥9 identifies patients with 4-year mortality exceeding 50%, qualifying them for intensive monitoring, regular sputum cultures, consideration of long-term macrolides, and referral to specialized bronchiectasis centers. The BSI also predicts healthcare utilization: each 1-point increase in BSI correlates with a 1.8-fold increase in hospitalization risk. The index has been externally validated in European, North American, Asian, and Australasian populations, demonstrating consistent performance across diverse healthcare systems.
Comparison with Alternative Bronchiectasis Scores
| Tool | Components | Primary Outcome | Validation Cohorts | Strengths/Limitations |
|---|---|---|---|---|
| BSI (Bronchiectasis Severity Index) | Age, BMI, FEV1%, prior hospitalizations, exacerbations, mMRC, Pseudomonas, radiological extent | Mortality, hospitalizations | >15,000 patients across 20+ cohorts | Most validated, predicts mortality and hospitalization; requires spirometry and CT |
| FACED Score | FEV1%, Age, Chronic colonization (Pseudomonas), Extent (radiological), Dyspnea | 5-year mortality | Spanish cohort (n=819), European validation | Simpler (5 variables), no exacerbation history; validated only for mortality |
| E-FACED Score | FACED + exacerbations (≥2/year) | Mortality and exacerbations | European cohorts (n=1,112) | Improves exacerbation prediction vs FACED; newer, less validated |
| Bronchiectasis Severity Scale (BSS) | Symptoms, signs, quality of life, radiology, microbiology, pulmonary function | Clinical worsening | Single center (n=102) | Complex, time-consuming; limited validation |
| REIFF Score | Radiological extent (HRCT scoring: cylindrical, varicose, cystic) | Exacerbation frequency | UK cohort (n=100) | Radiology-only; no clinical variables |
Exclusion Criteria and Limitations
Cystic fibrosis bronchiectasis (different pathophysiology and outcomes; CF-specific scores exist)
Patients with active pulmonary tuberculosis or non-tuberculous mycobacteria (NTM) infection without treatment (active infection confounds outcomes)
Bronchiectasis due to primary ciliary dyskinesia (PCD) - limited validation; lower mortality than non-CF bronchiectasis for same BSI score
Allergic bronchopulmonary aspergillosis (ABPA) - may have reversible component; BSI underestimates improvement with steroid therapy
Patients with lung transplantation (post-transplant bronchiectasis has different natural history)
Pregnancy (limited data; hormonal and mechanical changes affect respiratory status)
Acute exacerbation (BSI should be calculated during stable phase, at least 4 weeks after exacerbation resolution)
Etiology-Specific Performance
BSI predictive performance varies by underlying cause: Post-infectious bronchiectasis (most common, 40-50% of cases): C-statistic 0.84 for 4-year mortality (best performance). Idiopathic bronchiectasis (25-30%): C-statistic 0.80. COPD-associated bronchiectasis (15%): C-statistic 0.76 (lower due to competing cardiac/pulmonary mortality). Connective tissue disease-associated (RA, Sjögren's, 5%): C-statistic 0.79. Immunodeficiency (CVID, IgG subclass deficiency, 5%): C-statistic 0.82. The BSI performs worst in ABPA (C-statistic 0.71) due to waxing/waning inflammatory component not captured by fixed variables. Post-transplant bronchiectasis not validated.
Related Scores in Practice
In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the Faced Score, E Faced Score, or the Reiff Score to formulate a comprehensive care plan.
Last Comprehensive Review: 2026